Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term antibody persistence after infant Hib-MenCY-TT versus ActHIB vaccination
2012-004060-22Phase 2
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Haemophilus influenzae type b and meningococcal vaccine and haemophilus influenzae type b vaccine in Haemophilus influenzae type b disease (Hib), meningococcal disease and meningococcal meningitis (2 cohorts), sponsored by GSK. Primary endpoint: Anti-PRP antibody concentrations.
02
Drugs
Haemophilus influenzae type b and meningococcal vaccinehaemophilus influenzae type b vaccine
03
Conditions
Haemophilus influenzae type b disease (Hib)meningococcal diseasemeningococcal meningitis
Beyond the preview
Go deeper on 2012-004060-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004060-22.